皓宸医疗
(002622)
| 流通市值：17.39亿 | | | 总市值：17.39亿 |
| 流通股本：8.40亿 | | | 总股本：8.40亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 163,503,563.1 | 756,709,758.78 | 523,639,966.97 | 313,632,742.87 |
| 营业收入 | 163,503,563.1 | 756,709,758.78 | 523,639,966.97 | 313,632,742.87 |
| 二、营业总成本 | 179,781,974.53 | 732,435,656.95 | 520,216,907.68 | 328,515,500.63 |
| 营业成本 | 88,077,775.6 | 371,344,654.98 | 261,977,888.47 | 164,232,283.15 |
| 税金及附加 | 547,552.85 | 2,290,738.46 | 1,709,862.49 | 1,256,576.38 |
| 销售费用 | 41,887,503.48 | 154,450,891.06 | 110,269,851.96 | 68,158,068.29 |
| 管理费用 | 36,353,366.81 | 142,156,430.9 | 101,846,621.34 | 66,164,369.15 |
| 研发费用 | 1,594,263.46 | 15,897,625.56 | 10,675,860.37 | 6,427,417.24 |
| 财务费用 | 11,321,512.33 | 46,295,315.99 | 33,736,823.05 | 22,276,786.42 |
| 其中:利息费用 | 8,485,924.86 | 44,630,037.8 | 27,578,026.89 | 17,577,589.79 |
| 其中:利息收入 | 251,066.83 | 1,781,954.92 | 1,554,731.62 | 288,755.9 |
| 加:公允价值变动收益 | - | 714,184.71 | - | - |
| 加:投资收益 | 9,359,248.59 | 18,178,250.76 | 24,302,264.4 | 20,010,711.47 |
| 资产处置收益 | 145,525.65 | 4,171,003.29 | 2,857,599.89 | 2,857,599.89 |
| 资产减值损失(新) | -145,729.27 | -92,371,046.3 | 387,819.71 | 387,819.71 |
| 信用减值损失(新) | 101,946.44 | -4,433,407.53 | -1,473,439.71 | -632,903.71 |
| 其他收益 | 205,821.01 | 6,028,437.23 | 5,029,857.36 | 3,852,086.84 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -6,611,599.01 | -43,438,476.01 | 34,527,160.94 | 11,592,556.44 |
| 加:营业外收入 | - | 4,697,844.3 | 389,791.65 | 282,407.46 |
| 减:营业外支出 | 128,293.14 | 15,372,533.26 | 317,484.12 | 271,297.04 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -6,739,892.15 | -54,113,164.97 | 34,599,468.47 | 11,603,666.86 |
| 减:所得税费用 | 285,389.17 | 4,146,379.04 | -567,060.74 | -151,846.22 |
| 六、净利润 | -7,025,281.32 | -58,259,544.01 | 35,166,529.21 | 11,755,513.08 |
| 持续经营净利润 | -7,025,281.32 | -58,259,544.01 | 35,166,529.21 | 11,755,513.08 |
| 归属于母公司股东的净利润 | -4,572,538.15 | -94,365,092.81 | 16,321,536.9 | 7,620,553.84 |
| 少数股东损益 | -2,452,743.17 | 36,105,548.8 | 18,844,992.31 | 4,134,959.24 |
| (一)基本每股收益 | -0.01 | -0.11 | 0.02 | 0.01 |
| (二)稀释每股收益 | -0.01 | -0.11 | 0.02 | 0.01 |
| 八、其他综合收益 | 900,341.54 | -23,036,986.32 | 2,068,352.31 | 1,080,596.95 |
| 归属于母公司股东的其他综合收益 | 900,341.54 | -23,036,986.32 | 2,068,352.31 | 1,080,596.95 |
| 九、综合收益总额 | -6,124,939.78 | -81,296,530.33 | 37,234,881.52 | 12,836,110.03 |
| 归属于母公司股东的综合收益总额 | -3,672,196.61 | -117,402,079.13 | 18,389,889.21 | 8,701,150.79 |
| 归属于少数股东的综合收益总额 | -2,452,743.17 | 36,105,548.8 | 18,844,992.31 | 4,134,959.24 |
| 公告日期 | 2024-04-29 | 2024-04-29 | 2023-10-31 | 2023-08-31 |
| 审计意见(境内) | | 带强调事项段的无保留意见 | | |